Lenvatinib, sintilimab combined interventional treatment vs bevacizumab, sintilimab combined interventional treatment for intermediate-advanced unresectable hepatocellular carcinoma

Table 3 A summary of adverse reactions in the bevacizumab plus sintilimab plus interventional treatment and lenvatinib plus sintilimab plus interventional treatment groups, n (%)

Variable	BeSiIT (n = 28)		LeSiIT (n = 50)		P value
	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4
Thrombocytopenia	8 (28.5)	2 (7.1)	9 (18.0)	0 (0.0)	0.335	0.059
Neutropenia	4 (14.3)	0 (0.0)	9 (18.0)	1 (2.0)	0.699	0.454
Hypertension	5 (17.9)	0 (0.0)	15 (30.0)	7 (14.0)	0.306	0.047a
Rash	4 (14.3)	0 (0.0)	8 (16.0)	1 (2.0)	0.853	0.454
Hand-foot skin reaction	4 (14.3)	0 (0.0)	8 (16.0)	1 (2.0)	0.853	0.454
Abdominal pain	1 (3.6)	0 (0.0)	3 (6.0)	1 (2.0)	0.649	0.454
Bleeding	1 (3.6)	0 (0.0)	7 (14.0)	0 (0.0)	0.167	-
Fever	2 (7.1)	0 (0.0)	0 (0.0)	0 (0.0)	0.059	-
Nausea	0 (0.0)	0 (0.0)	10 (20.0)	0 (0.0)	0.018a	-
Decreased appetite	1 (3.6)	0 (0.0)	12 (24.0)	0 (0.0)	0.033a	-
Diarrhea	0 (0.0)	0 (0.0)	10 (20.0)	0 (0.0)	0.018a	-
Fatigue	2 (7.1)	0 (0.0)	16 (32.0)	2 (4.0)	0.027a	0.290
Vomiting	0 (0.0)	0 (0.0)	8 (16.0)	0 (0.0)	0.034a	-
Proteinuria	8 (28.5)	0 (0.0)	5 (10.0)	0 (0.0)	0.053	-
Hyperbilirubinemia	6 (21.4)	0 (0.0)	11 (22.0)	0 (0.0)	0.958	-
Elevated ALT	2 (7.1)	0 (0.0)	8 (16.0)	0 (0.0)	0.293	-
Elevated AST	6 (21.4)	0 (0.0)	13 (26.0)	1 (2.0)	0.693	0.677
Hypoalbuminemia	2 (7.1)	0 (0.0)	7 (14.0)	0 (0.0)	0.391	-

^aP value < 0.05, and it is statistically significant.

BeSiIT: Bevacizumab plus sintilimab plus interventional treatment; LeSiIT: Lenvatinib plus sintilimab plus interventional treatment; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase.